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Abstract 
 In October 2007 the state of Tennessee began enforcement of a workplace 
smoking ban now known as the “Non-Smoker Protection Act”. In an effort to help local 
health departments be well positioned to assist individuals with smoking cessation the 
Department of Health rolled out a patient assessment and treatment program. For best 
results, this program can take an epidemiological approach. Epidemiology is defined as 
the study of the distribution of determinants and antecedents of health and disease in 
human populations, with the goal of identifying their underlying causes and ultimately 
the application of findings for disease prevention and health promotion (Turnock 387). 
By understanding some key characteristics of the patients our providers encounter, such 
as socioeconomic status and nicotine dependence, we can develop cost effective 
strategies to achieve optimum success with the smoking cessation program. 
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Introduction 
Background 
 
 One of public health’s greatest conquests began over forty years ago and the story 
of the Tobacco Epidemic continues to play out on the world stage. Since the 1964 Report 
of the Advisory Committee to the Surgeon General, entitled Smoking and Health, there 
have been twenty-eight other reports issued from the U.S. Public Health Service 
concerning the health risks associated with Tobacco use (Office on Smoking and Health 
1).  These twenty-nine reports have described in detail the direct association of smoking 
with lung and other cancers, chronic obstructive lung disease, respiratory infections, 
asthma, cardiovascular disease, low birth-weight, and a myriad of other poor health 
outcomes (CDC
2
 986; EPA 6; Mokdad 1238). There is empirical evidence that smoking 
is the single largest preventable cause of death and disability in the United States.   
 Beginning in the 1990s, this overwhelming body of evidence led to several states 
filing law suits against tobacco companies seeking recovery of costs associated with the 
treatment of smoking related illnesses. In 1998, the Attorneys General of 46 states signed 
the Master Settlement Agreement with the four largest tobacco companies (Phillip 
Morris, RJ Reynolds, Brown and Williamson, and Lorillard) in the United States to settle 
these law suits (Office on Smoking and Health 2).  One of the major effects of this 
agreement was the establishment of the National Foundation.  This non-profit foundation, 
established by the Executive Committee of the National Association of Attorneys 
General (NAAG), is the vehicle that delivers funds secured from the settlement to support 
the prevention of diseases associated with tobacco use (Hermer 1). 
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 Landmark reports and court settlements have paved the road public health 
professionals are currently taking to prevent tobacco related morbidity and mortality. The 
goals and objectives related to tobacco control are explicitly described by the U.S. 
Department of Health and Human Services. National health objectives focused on the 
year 2010 have been issued by DHHS, referred to as Healthy People 2010. Those 
objectives target prevalence of tobacco use by designating it as one of the top ten leading 
health indicators (Turnock 76).  Objectives within the focus area of tobacco according to 
Healthy people 2010 are as follows: target a reduction of the current smoking prevalence 
among adults to 12%, among students in grades 9-12 to 16%; increase smoking cessation 
attempts by adults to 75%, increase smoking cessation attempts by adolescents to 64%; 
increase smoke-free environments of schools and workplaces to 100% (National Center 
for Health Statistics 1). 
Tennessee Tobacco Control Efforts 
 
 Tobacco control efforts throughout the United States employ a variety of 
strategies to reach the Healthy People 2010 targets. Effectively diminishing the toll taken 
by tobacco on the public’s health has been achieved by raising cigarette prices through 
state excise taxes, establishing social support through telephone counseling, and enacting 
clean air laws or smoking bans (Chaloupka 62; Maher 65; Heironimus 1). Furthermore, a 
synergistic effect is clearly demonstrated when multiple control efforts are employed at 
once (Hopkins 42). Tennessee is an example of one such place where multiple control 
efforts are being used to close in on the targets set forth in Healthy People 2010.  On June 
11, 2007, Governor Phil Bredesen signed the “Non-Smoker Protection Act” into law in 
Tennessee, which makes it illegal to smoke in most places where people work (Tennessee 
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Department of Health 
1
).  The workplace smoking ban was followed by a tax increase of 
forty-two cents per pack, only the third in state history, which increased the tax from 
twenty cents to sixty-two cents per pack. 
 The local health departments in Tennessee are well-positioned to take advantage 
of one of the best suited environments to tackle the tobacco problem. With multiple 
tobacco control efforts firmly in place, a new patient assessment, tobacco use survey, and 
cessation assistance program was rolled-out with enthusiasm across the state. The 
smoking status of all patients encountered at the local health departments over the age of 
thirteen is now being assessed. At each point during a patient’s visit (registration, 
provider consultation, check- out) they are assessed for potential enrollment into the 
smoking cessation program. Additionally, consenting patients are referred to the 
Tennessee Tobacco Quitline. This telephone service provides personalized support for 
Tennesseans who want to quit smoking by assigning them a quit-coach for one-on-one 
counseling during quit attempts (Tennessee Department of Health 
2
). This free of charge 
service is available without referral from a provider as well. 
  For those patients who enroll in the cessation and treatment program, the local 
health department is providing access to non-prescription nicotine replacement therapy in 
the form of nicotine gum or lozenges.  Chantix, a pharmaceutical therapy that controls the 
response of nicotine receptors in the brain, is also being made available to patients for 
whom it is indicated. This requires an evaluation by a physician, or a mid-level provider, 
and a prescription. A sliding-fee scale is administered to determine the charge to the 
patient for the services and associated medicines. Figure 1 shows the survey instrument 
used to collect information and assess patient readiness. 
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(Figure 1.) Courtesy of the Tennessee Department of Health Bureau of HSA 
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Tobacco Epidemiology 
 
 The fundamental perspective linking each of Tennessee’s tobacco control efforts 
is that of epidemiology. That is the study of the distribution of determinants and 
antecedents of health and disease in human populations, with the goal of identifying their 
underlying causes and ultimately the application of findings for disease prevention and 
health promotion (Turnock 387).  Figure 2 provides an epidemiologic model that 
identifies the agent, host, vector, and environment as they relate to tobacco control 
(Giovinio7326).  
(Figure 2) From Epidemiology of tobacco use in the United States Gary A Giovino. 
 
Each piece plays a specific role in the chain of events that lead to the outcome of 
cigarette smoking. They also represent a place or an opportunity to engage the process 
and reduce the prevalence of the undesired outcome. The agent, tobacco products, is 
easily described and well understood. As for the environment, the new state cigarette tax 
increase, non-smoker protection laws, and access to cessation assistance contribute to the 
current atmosphere of confronting the tobacco use challenge. In consideration of the 
vector, the tobacco product manufacturers and other users account for smoking initiation 
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and the development of nicotine addiction. Describing the host requires a closer 
examination of this specific population in Tennessee. 
 To best understand how the smoking population in the state of Tennessee 
compares to the rest of the United States, we can look to information collected by the 
Centers for Disease Control and Prevention, CDC. The Behavioral Risk Factor 
Surveillance System, BRFSS, is a state-based system of health surveys, established by the 
CDC in 1984 that collects information on health risk behaviors such as the prevalence of 
tobacco use (CDC 
1
).  When the 2005 data were published in April of the following year, 
a smoking prevalence of 26.7% of the population over age 18 in Tennessee gave them a 
ranking of 47
th
, tied with West Virginia, in the U.S. (United Health Foundation 1). This 
was a full 6.1% higher than the national prevalence of 20.1% and really gave legislators 
something to reflect upon as the Non-Smoker Protection Act was being prepared for its 
introduction to the state senate. 
 The 2006 data from the BRFSS show some change has occurred in the 
prevalence. Adults who were current smokers in Tennessee made up 22.6% of the 
population compared to the 20.0% prevalence for the rest of the nation (CDC 
1
).  Figure 3 
provides a comparison of the 2006 reported prevalence and the Healthy People 2010 
goal. BRFSS also collects specific information related to smoking status. 
(Figure 3). 
 
0
50
100
 smoking 
status 
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2006 smoking prevalence compared to 
Healthy People 2010 Goal
Adult smokers 22.6 20 12
Adult non-
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TN U.S.
2010 
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11 
 
An even closer examination of the differences between the state and national levels offers 
crucial evidence for tailoring smoking cessation efforts in Tennessee. Figure 4 represents 
information about frequency (every day or some days) and history (former smoker or 
never smoker) of smoking status in 2006. The readily obvious disparity in the four  
(Figure 4). 
0
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levels of smoking status between Tennessee and the rest of the nation are found among 
the number of every day smokers. Our state had 3.7% more every day smokers than the 
rest of the U.S. in 2006 (CDC 
1
). On the surface the difference indicates that Tennessee’s 
population of current smokers has a heavier level of addiction and a potentially lower 
level of success with cessation. 
Important Variables of Smoking Cessation 
 
 To see beyond the surface we must consider the factors involved with nicotine 
addiction and quitting smoking successfully. Various studies and surveys have examined 
an array of variables that are thought to determine the likelihood of individual success 
with smoking cessation. Among the “core predictor values” that have been explored 
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regarding cessation success are socioeconomic status, or SES, and other demographic 
factors such as race and gender (Keiko 375). There are the motivational concepts and 
belief systems that have been linked to both addiction and cessation. These include self 
efficacy, outcome expectancy, worries about health and quality of life, and overall 
attitudes about smoking. Past quitting histories and nicotine dependence variables have 
been given a statistical analysis as well (A Hyland 85).  Researchers have also considered 
conditions that may be sources of unsuccessful quit attempts like emotional distress and 
alcohol use (Erik 549). 
 For an exploration of the association between Socioeconomic Status, or SES, and 
smoking cessation a description of the SES measure in epidemiologic studies is 
incumbent upon the journey. Seventy six studies reported in the American Journal of 
Epidemiology in 1982 and 1985 were examined by researchers to see how many 
considered social class a variable related to a chronic disease outcome. Nearly 40 percent 
of those studies looked for the effect of social class upon health outcomes and could be 
more specifically detailed as follows: 42% considered SES to be a potential confounder, 
32% viewed SES as a risk factor, and 26% of these studies used SES as a variable 
descriptive of the study sample (Liberatos 87). 
 Since many of the patients encountered at the local health department tend to have 
lower socioeconomic status, or SES, it is possible that certain trends exist within this 
population.  Higher levels of nicotine dependence, having low self-efficacy to quit, and 
having no intention to quit are correlated with both low SES and low likelihood of 
success with smoking cessation (Siahpush 71). The tobacco survey and assessment tool 
can be used to make this information immediately available to our healthcare providers. 
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Additionally, some studies show that this social gradient is not limited to the prevalence 
of smoking, but also differs among smokers between socioeconomic groups, suggesting 
that individuals of lower SES don’t just smoke, they smoke more intensely (Bobak 311).  
Even though these critical factors most likely form a continuum along which our patients 
exist, it is important to recognize how each one can impact the final outcome. 
Information for Action 
 Understanding the links between the key characteristics of Tennessee’s smoking 
population, specifically the patients encountered at the local health departments, and the 
Healthy People 2010 target prevalence can help us yield actionable information. One 
other benefit will be the ability to develop clever strategies and innovative tactics with 
limited financial resources while implementing the smoking cessation program at the 
local level. Since the local program consists of access to several therapies, two different 
nicotine replacement therapies and one prescription for a nicotine receptor inhibitor, 
benefits could be realized from the predictive value of patient characteristics. Inferences 
from the characteristics can be directed at the most efficacious course of treatment for 
patients who enroll in the cessation program, thus using the more expensive course of 
treatment only when indicated as the most effective and taking appropriate steps to better 
position patients for success. 
 A discussion if the cost of the program is integral to the development of the 
approach. Patients who receive this service are charged according to the sliding fee scale. 
If they have private insurance, the company will be billed for the service. The rate of pay 
for the uninsured is a function of their reported income. The vast majority of the patients 
with private insurance or with moderate to high incomes (both indicators of moderate to 
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high SES) tend to seek smoking cessation therapy with a private primary care provider. 
Even though the smoking cessation program is available for all who seek assistance, 
patients encountered at the local health departments are predominantly from the lower 
SES categories. 
  When considering the cost of cessation treatment, it is important to note that the 
full course of therapy is ninety days. A three month supply of nicotine gum costs 
$139.51, and is the least expensive form of nicotine replacement therapy. For individuals 
with temporomandibular joint, or TMJ, syndrome and others for whom chewing gum 
may be contraindicated, a three months supply of lozenges costs $366.03. The third 
course of treatment requires a prescription. Varenicline (also known as Chantix 
manufactured by Pfizer) costs $279.92 per three month supply per patient. The twofold 
increase in the cost of the Chantix compared to the nicotine gum is compounded by the 
requirement for a prescription. The chewing gum and lozenges can be dispensed by a 
nurse and do not require written approval by a Physician. Figure 5 summarizes this data. 
(Figure 5). 
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departments in Tennessee. A fundamental component to developing best practices can be 
found in the inverse relationship between cigarette consumption and cessation rates. It is 
well established that cessation rates are much higher among individuals with lowest 
levels of nicotine consumption. In order to increase cessation rates among those 
individuals with high levels of nicotine consumption (i.e.; the majority of our patients, 
based on the correlation of consumption and socioeconomic status,) our program may 
benefit from interventions that first reduce consumption to lower levels and indirectly 
boost subsequent cessation rates (A Hyland 92). A review of the existing literature 
demonstrates a correlation between patient characteristics and cessation which can be 
used to develop best practices by our providers in prescribing cessation treatment. 
Literature Review 
 
Socioeconomic Status (SES) and Smoking Cessation 
  The establishment of SES as an etiological agent of disease is rather 
commonplace, however recent literature suggests it is known to be related specifically to 
smoking cessation. In a 2005 cross-sectional study of smoking initiation and cessation 
SES was categorized as High Medium and Low with education level of the respondent as 
the basis. The resulting odds ratios among men of smoking cessation within each level 
were 1.0 for Low SES, 1.53 for Medium SES and 2.38 for High SES. Results among 
women were 1.0, 1.44 and 1.79 respectively (A. Jeanne 259).   
 Some studies set SES levels according to occupation. In a survey of a population 
sample from Sweden in 1994 the effect of SES on successful smoking cessation was 
much like the 2005 cross-sectional study. The highest levels of SES were associated with 
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a twofold increase in smoking cessation. (Lindstrom 201). Figure 6 reports the findings 
of smoking cessation as it relates to these SES levels. 
Figure 6. Smoking Cessation in Relation to Socioeconomic Variables (Lindstrom 204). 
SES  levels by occupation  Men Odds Ratio (95%CI) Women Odds Ratio (95%CI) 
V   Unskilled manual workers 1.0 1.0 
IV Skilled manual workers 1.5 (1.1 ± 1.9) 1.3 (0.9 ± 1.8) 
III Low-level non-manual 
workers 
1.8 (1.4 ± 2.4) 1.5 (1.2 ± 1.8)  
II Mid-level non-manual 
workers 
2.0 (1.5 ± 2.5) 1.7 (1.4 ± 2.2) 
I Non-manual workers in 
leading positions 
1.9 (1.4 ± 2.5) 2.0 (1.4 ± 2.7) 
VI Self-employed 1.4 (1.1 ± 1.8) 1.5 (1.1 ± 2.1) 
VII disability pensioners < age 
65 
1.4 (1.1 ± 1.8) 1.2 (1.0 ± 1.5) 
VIII Unemployed 1.0 (0.8 ± 1.4) 1.2 (0.9 ± 1.7) 
 
 In 2003, research that speaks directly to health department patient demographics 
was conducted using information from the Australia Bureau of Statistics. Data collected 
in the 1998–99 Household Expenditure Survey allowed researchers to make a connection 
between SES and the proportion of household income used to purchase tobacco. Not only 
did the study confirm earlier findings that lower education level, occupational status, 
living in rented housing, or in disadvantaged areas were associated with higher tobacco 
expenditure as a percentage of household expenditure, but it also demonstrated that a 
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social gradient exists where the lower SES group consume more cigarettes and thus are 
more addicted to nicotine (Siahpush 801). 
 The effects of higher prevalence of smoking among individuals with lower SES 
were clearly demonstrated in a study exploring how decreases in cardiovascular mortality 
were predominantly experienced among the most educated within a cohort. Multiple 
studies conducted between 1960 and 1993 in Denmark were evaluated to explain how 
increased social inequality in cardiovascular mortality might be associated with different 
trends in behavioral cardiovascular risk factors in different educational groups. From 
1982 to 1992 the prevalence of smoking decreased mainly among individuals with higher 
SES, based on education level, and served to widen an existing gap. The increased 
socioeconomic difference in cardiovascular mortality during the 1980s in Denmark was 
found to be attributable to the difference in the prevalence of smoking between the 
different levels of SES (Osler 112). 
 Analysis of a biological marker for nicotine addiction has provided considerable 
evidence that the lower socioeconomic groups in society are the heaviest smokers. Data 
used to monitor trends in cardiovascular diseases in the Czech Republic included 
observed levels of serum thiocyanate, a biological marker used to determine nicotine 
intake. The 1999 study found that serum thiocyanate concentrations were inversely 
associated with education among men. This social gradient was not limited to the 
prevalence of smoking, but also differed among smokers between groups, suggesting that 
individuals of lower SES don’t just smoke, they smoke more intensely (Bobak 311). 
 The correlation between SES and how current smokers become former smokers 
has been under evaluation for decades. Research in 1987 took data from an ongoing case-
18 
 
control study that included 3,778 male and 1,486 female ever-smoking patients 
hospitalized with non-tobacco-related conditions. Patient interviews were conducted 
between 1977 and 1985. The lifetime quit rate, [no. ex-smokers/no. ever smokers] x 100, 
was found to increase with increasing educational and occupational level in both male 
and female patients (Kabat and Wynder 1301). Figure 7 reports findings from the study. 
Figure 7. (Kabat and Wynder 1302). 
                  
 
 
 
 
 
Nicotine Dependence and Cessation Success 
 A discussion of the measurement nicotine dependence will help develop our 
understanding of its influence on the outcome of patient success with smoking cessation.  
The Heaviness of Smoking Index (HSI) is the sum of two categorical measures: number 
of cigarettes smoked per day (coded: 0: 0–10 cigarettes per day (CPD), 1: 11–20 CPD, 2: 
21–30 CPD, 3: 31+ CPD), and time to first cigarette (coded: 0: 61+min, 1: 31–60 min, 2: 
6–30 min, 3: 5 min or less).Values for this variable range from 0 to 6. This index is 
positively associated with nicotine dependence (Heatherton 791).  Another method used 
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to index nicotine dependence is called the Fagerstrom Tolerance Scale. The questionnaire 
administered to determine nicotine dependence with this method is shown in Figure 8. 
Figure 8. (Heatherton 1127). 
 
 
 
  
 Beginning in 2002 the United States, Canada, Australia, and the United Kingdom 
began a prospective cohort study that was aimed at evaluating the behavioral impact of 
national tobacco control policies. Referred to as the International Tobacco Control Four 
Country Survey, the study uncovered prominent similarities between the countries with 
regards to nicotine dependence and smoking cessation. A strong relationship between the 
percent of smokers in the entire sample that quit and their HSI scores provide evidence 
that cessation is much more successful at lower levels of nicotine dependence. For 
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example of the entire sample that made serious quit attempts 14% quit with a HSI of 6, 
22% quit with a HSI of 3, and 39% quit with a HSI score of 0 (A. Hyland 88). 
 Canada’s National Population Health Survey was recently analyzed to determine 
if statistically significant associations existed between specific HSI levels and success 
with smoking cessation. The results were found to be immediately relevant to the 
characteristics of our patients. The study focused on the 2,938 adult respondents who 
were daily smokers in 1996-97. According to the survey people reporting low levels of 
nicotine dependence as measured by HSI were most likely to report quitting successfully.  
Even though some of the smokers with a higher level of nicotine dependence experienced 
successful quit attempts, they were found to be older wealthier individuals, suggesting 
that SES is a mediating factor (Chaiton 1039). 
 A recent study conducted to identify individual characteristics that predict 
successful smoking cessation treatment in African Americans provides solid evidence of 
the link between nicotine dependence and cessation. Smoking after 30 minutes of waking 
and smoking fewer cigarettes per day were both found to be statistically significant 
predictors of cessation. Patients enrolled in the study that reported smoking within 30 
minutes of waking were found to have considerably less success with smoking cessation 
(approximately 60% less success) than those that did not (Harris 498).  
 In a cohort of Danish men and women, aged 30–60 years at first examination in 
1982/1984, smoking behavior was evaluated from questionnaires at baseline and 
at follow up 10 years later to see how known determinants of successful cessation 
interacted across varying levels of motivation to stop smoking. The amount of tobacco 
smoked, a main contributor to HSI scores, was discovered to be strongly associated with 
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smoking cessation among individuals in the study. The odds ratio of successful cessation 
dropped from 1 to 0.44 when number of cigarettes smoked per day went from 0-10 to 
>10 (Osler 266).  
 In one of the first studies to prospectively evaluate variables predictive of success 
in stopping smoking, an index of nicotine dependence was based upon three items from 
the Fagerstrom Tolerance Scale. Respondents who scored higher on the nicotine 
dependence index were more likely to have less confidence in their ability to quit and 
stay off cigarettes, while those who reported smoking more cigarettes daily were less 
likely to be successful in stopping. The multivariate odds ratio for successful quitting 
with the variable of smoking fewer cigarettes daily was 1.9 (Hellman 84). 
Treatment guidelines for Specific Populations 
 There is little scientific evidence available that is currently being used to match 
individuals with specific forms of smoking cessation therapy. The majority of 
randomized controlled trials that were employed to explore the efficacy of the various 
nicotine replacement methods enrolled individuals who were smoking >15 cigarettes per 
day. Considering the lower socioeconomic status and higher nicotine dependence of our 
patient population, Tennessee’s local health departments will likely encounter people 
who smoke at least as many as 15 cigarettes a day or more. The majority of treatment 
guidelines have been based upon the rather intuitive concept that level of nicotine 
dependence and the dose of nicotine prescribed for replacement are directly proportional.  
  A 2001 international study of the use of nicotine lozenges shows that although 
highly nicotine dependent smokers were less successful at abstaining when treated with 
placebo, treatment with the active lozenge eliminated the excess failure due to 
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dependence and helped high-dependency smokers achieve outcomes comparable to those 
of low-dependency smokers (Shiffman1279). Smokers were assigned to a lozenge dose 
on the basis of nicotine dependence, assessed by time to the first cigarette of the day. 
Low-dependence smokers were randomized to receive the 2-mg nicotine or placebo 
lozenge; high-dependence smokers, the 4-mg nicotine or placebo lozenge. Figure 9 
contains the detailed observations of the treatment efficacy across nicotine dependence 
levels. 
Figure 9. (Shiffman1271). 
 
 In 2004 researchers were able to demonstrate a difference between smoking 
abstinence rates for highly nicotine dependent patients and those with low to moderate 
dependence based upon their assignment to specific nicotine replacement therapies. 
Smokers who had low to moderate dependence levels achieved higher abstinence rates 
with trans-dermal nicotine replacement therapy, whereas smokers who were highly 
dependent achieved higher abstinence rates with nasal spray. The results from the study 
suggest that the ability to self administer nicotine nasal spray when desired and the 
reinforcing effects of more rapidly delivered nicotine are important factors in facilitating 
abstinence for more highly dependent smokers (Lerman 431). 
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 With the limited amount of research available to guide decision making when 
assigning specific cessation therapy to patients, it is important to note the existing 
guidelines proposed by the U.S. Public Health Service. Even though level of nicotine 
dependence is not among the factors clinicians are currently considering when selecting a 
course of treatment, there are other considerations to make. Because of the lack of 
sufficient data to rank-order cessation therapies, choice of a specific first-line 
pharmacotherapy must be guided by factors such as clinician familiarity with the 
medications, contraindications for selected patients, patient preference, previous patient 
experience with a specific pharmacotherapy [positive or negative], and patient 
characteristics [e.g., history of depression, concerns about weight gain] (Fiore 26). 
  Choosing which method to prescribe to whom is only one aspect of developing 
sound treatment guidelines. Duration of therapy is a significant aspect as well. According 
to meta-analysis of 21 published, randomized, controlled clinical trials, comparing 
nicotine replacement therapy [NRT] to placebo the average treatment duration was found 
to be 145 days. The study found the protective effect of NRT against relapse slowly 
decreases as a function of time. After stopping NRT, the risk of relapse increases, 
suggesting it may be more beneficial not to stop NRT after the usual 3-6-month treatment 
period but to use NRT for longer periods of time (Medioni 247). 
 Studies on extending the use of prescription Varenicline, also known as Chantix, 
demonstrate a protective effect by increasing the duration of treatment. Patients that had 
been treated for 12 weeks with Varenicline and were abstinent during the last week of 
treatment were enrolled in the trial. Participants were randomly assigned to receive either 
double-blind Varenicline or placebo for an additional 12 weeks. The continuous 
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abstinence rate was significantly higher for the Varenicline group than for the placebo 
group for weeks 13 to 24 with more than twice the number of patients prevented from 
relapsing (Tonstad 64). 
Development of Best Practices 
Implications 
 The research indicates that the majority of the patients we will encounter at the 
local health departments in Tennessee are less likely to have success with smoking 
cessation due to their lower socioeconomic status, or SES. The fact that individuals of 
lower SES experience a higher level of nicotine addiction accounts for fewer successful 
quit attempts in this population. While very little scientific evidence exists to match 
patients with specific smoking cessation therapies, guidelines to treat our population 
should be developed with these characteristics in mind. 
 With an assessment tool already in place (see Figure 1) the addition of two simple 
questions would allow for the enumeration of a patient’s nicotine addiction level. By 
asking the number of cigarettes smoked per day (coded: 0: 0–10 cigarettes per day 
(CPD), 1: 11–20 CPD, 2: 21–30 CPD, 3: 31+ CPD), and time to first cigarette (coded: 0: 
61+min, 1: 31–60 min, 2: 6–30 min, 3: 5 min or less) a simplified Heaviness of Smoking 
Index (HSI) score can be assigned and goals can be determined. Patient progress towards 
a lower score can be tracked during follow-up visits with an ultimate goal of successfully 
quitting. 
 I would recommend that patients with an HSI of 5 or 6 begin with the highest 
level of Nicotine Replacement Therapy, using the gum unless contraindicated since the 
ability to self administer therapy and the reinforcing effects of more rapidly delivered 
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nicotine are important factors in facilitating abstinence for more highly dependent 
smokers (Lerman 431). Based upon the cost of the therapy alone, twice the number of 
patients with HSI scores of  5 or 6 can be treated with nicotine gum compared to the 
Chantix (see figure 5). Because patients with lower HSI scores have experienced as much 
as an 8% higher success rate (A. Hyland 88), the use of Chantix when indicated can be 
considered for those with an HSI below 5 allows for a targeted approach of the more 
expensive resource.  
 The targeting of health department resources by assignment of the Heaviness of 
Smoking Index score is described in the following flow chart found in Figure 10. 
Figure 10. 
 
First encounter patients are assessed and given a 
Heaviness of Smoking Index score 
HSI 5-6 receive 
nicotine gum/ 
scheduled for 
follow-up. 
 
*Prescribe 
lozenges when 
medically 
necessary 
HSI 0-4 receive 
nicotine gum or 
Chantix/ 
scheduled for 
follow-up. 
 
*Prescribe 
lozenges when 
medically 
necessary 
 
 
 
HSI 0-4 receive nicotine 
gum or Chantix/ 
scheduled for follow-up. 
 
HIS 5-6 after 
follow-up 
continue NRT/ 
schedule for 
follow-up exam. 
 
Final follow-up visit. Dispense 
or prescribe preferred smoking 
cessation therapy.  
 
Ensure patient is enrolled with 
Tennessee Quitline for 
continued social support and 
counseling. 
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This model suggests that for patients presenting with scores of 5 or higher receive 
appropriate and cost-effective Nicotine Replacement Therapy (NRT) initially. When 
follow-up visits reveal diminished nicotine dependence (HSI <4), then prescribe more 
NRT or Chantix. 
 Based upon the clinical guidelines put forth by the U.S. Public Health Service All 
smokers trying to quit should receive pharmacotherapy for smoking cessation, except in 
the presence of special circumstances (Fiore 26). Controlled clinical trials and statistical 
analysis of multiple studies suggest that increasing the average duration of smoking 
cessation therapy leads to greater success with quit attempts. Because these trials and 
studies have examined nicotine gum, nicotine lozenges, and Chantix, it is recommended 
extending the current duration of therapy as far beyond 90 days as resources will allow. 
The flow chart in Figure 10 was designed with the assumption that 90+ days of therapy 
will be available.  While outside the scope of this paper, future steps should include 
further research in the efficacy and cost effectiveness of this approach. 
Conclusions 
 The Tobacco Cessation Program in Tennessee is one of the most significant 
attempts to reduce smoking prevalence in the history of our state. The morbidity and 
mortality of smoking related illness takes a tremendous toll on our population, and has 
the potential to disproportionately affect those of lower socioeconomic status. The local 
health departments are in a unique position to provide an essential service by getting the 
needed smoking cessation therapies to individuals that may not otherwise have access. 
Characteristics of the patient population should be considered in the design of a treatment 
protocol. 
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 Making minor adjustments to the assessment tool that provide a Heaviness of 
Smoking Index score and extending the duration of therapy could lead to more successful 
quit attempts. Ultimately the program will benefit from interventions that first reduce 
consumption to lower levels and indirectly boost subsequent cessation rates. The use of 
an epidemiological approach has primarily considered the relationship of the host and the 
environment within the scope of our tobacco cessation program. Applying what we know 
about the host is the fundamental aspect of this approach, and should help us achieve an 
optimal success rate.    
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